ABT-165

DRUG2 trials

Sponsors

AbbVie

Conditions

Advanced Solid TumorsCancer

Phase 1

A Study of ABT-165 in Subjects With Solid Tumors

CompletedNCT01946074

AbbVieAdvanced Solid Tumors

Start: 2013-08-08End: 2022-09-28Updated: 2023-12-15

Phase 2

A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

TerminatedNCT03368859

Start: 2018-03-20End: 2019-12-18Updated: 2021-02-09

Related Papers

Efficacy and Safety of Dilpacimab (ABT-165) versus Bevacizumab Plus Folfiri in Metastatic Colorectal Cancer: A Phase II Study

Future Oncology2022-08-039 citations

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

Molecular Cancer Therapeutics2021-07-2613 citations

ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.

Journal of Clinical Oncology2019-01-291 citations

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)

Annals of Oncology2018-06-015 citations

ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress

Annals of Oncology2018-06-01

ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.

Journal of Clinical Oncology2018-05-202 citations

Phase 1, open-label, dose-escalation and expansion study of ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting both DLL4 and VEGF, in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2016-05-204 citations